Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Open Forum Infectious Diseases Année : 2022

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience

Davide Caimmi

Résumé

Background Mycobacterium abscessus infections remain difficult to manage in both cystic fibrosis (CF) and non-CF patients and reported clinical outcomes are largely unsatisfactory. Clinical trial data are limited and no approved therapies are currently available for the management of M abscessus lung diseases. As an alternative, cohort studies may provide insightful information into the management of M abscessus pulmonary disease.Methods Based on a retrospective observational cohort study, we investigated the safety and efficacy of amikacin liposome inhaled suspension (ALIS) as an adjunct to a standard antibiotic regimen for M abscessus lung infection in both CF and non-CF patients. We also assessed the association of patient drug compliance with culture conversion and clinical outcomes.Results Twenty-six patients had long-term follow-up data available. Culture conversion was achieved in 54% (14/26) of the patients with no difference between CF and non-CF patients after an average treatment duration of 10 months. Patient treatment compliance was significantly better in the converter group compared to nonconverters with an odds ratio of 44.78 associated with good compared to poor patient compliance. Overall, 9 patients (35%) experienced an adverse event that led to treatment discontinuation.Conclusions ALIS appears beneficial in both CF and non-CF populations with M abscessus lung disease.
Fichier principal
Vignette du fichier
2022 Chiron et al., Amikacin.pdf (28.63 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Licence : CC BY - Paternité

Dates et versions

hal-03824298 , version 1 (21-10-2022)

Licence

Paternité

Identifiants

Citer

Raphael Chiron, Wouter Hoefsloot, Jakko van Ingen, Hélène Marchandin, Laurent Kremer, et al.. Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience. Open Forum Infectious Diseases, 2022, 9 (10), pp.ofac465. ⟨10.1093/ofid/ofac465⟩. ⟨hal-03824298⟩
103 Consultations
6 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More